# A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects

> **NCT02440633** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Bacterial Enteritis

## Interventions

- **DRUG:** 14C-OPS-2071

## Key facts

- **NCT ID:** NCT02440633
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2016-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02440633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02440633, "A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02440633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*